Skip to main content
. 2020 Jan 27;318(3):F647–F659. doi: 10.1152/ajprenal.00288.2019

Fig. 5.

Fig. 5.

Renal effects of 18E1 monoclonal antibody (mAb) in CD148 knockout (CD148KO) diabetic mice. A: blood glucose (BG), systolic blood pressure (SBP), left kidney weight-to-body weight ratio (LKW/BW), and urinary albumin-to-creatinine ratio (ACR) were measured in CD148KO diabetic [streptozotocin (STZ)] or nondiabetic (control) mice treated with 18E1 mAb or control IgG for 6 wk. n = 8 mice/group. Data are presented as means ± SE. Note that 18E1 mAb did not decrease albuminuria in CD148KO diabetic mice. B–F: renal histopathology [B; periodic acid-Schiff (PAS) stain], mesangial expansion scores (C), F4/80 macrophage infiltration (D), nephrin immunoreactivity (E), and podocyte number (F) were assessed in CD148KO diabetic (STZ) and nondiabetic (control) mice treated with 18E1 mAb or control IgG for 6 wk as in Fig. 4. n = 8 mice/group. Data are presented as means ± SE. Scale bar = 25 µm in B and D−F.